Cogent Biosciences (COGT) Jefferies Global Healthcare Conference 2026 summary

Company overview and financial position

• Focuses on novel small molecule treatments for rare diseases caused by mutations, with lead asset bezuclastinib under FDA review for multiple indications including GIST and systemic mastocytosis.

• Holds nearly $870 million in cash, sufficient to fund operations and product launches well into 2028.

• Preparing for commercial launch of bezuclastinib later this year, with additional early-stage assets in development targeting high unmet medical needs.

Clinical trial results and medical meeting highlights

• Phase III PEAK study showed bezuclastinib plus sunitinib significantly improved median progression-free survival (16.5 vs. 9.2 months) over sunitinib alone in second-line GIST, with a hazard ratio of 0.5.

• Consistent efficacy observed across genotype subgroups and improved long-term outcomes indicated by PFS-2 analysis.

• Mean duration of treatment reached 21.4 months, more than doubling historical sunitinib averages.

• Real-world use may see even longer treatment durations due to continued therapy post-progression.

Physician and patient feedback

• Strong enthusiasm from both physicians and patients for the bezuclastinib and sunitinib combination, with expectations it will rapidly become the new standard of care for second-line GIST upon approval.

• Anticipated rapid uptake due to ability to add bezuclastinib to existing sunitinib regimens.